Clinical Trials on Lymphedema, Breast Cancer in Belgium

Total 1822 results

Bristol-Myers Squibb

Completed

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

Melanoma | Lung Cancer

United States, Australia, Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Puerto Rico, Spain, Switzerland, United Kingdom
ARCAGY/ GINECO GROUP
Hoffmann-La Roche

Active, not recruiting

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (ATALANTE)

Ovarian Cancer

Spain, Belgium, France, Germany, Austria, Czechia, Israel
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
Amgen

Terminated

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)

Gastric Cancer

United States, Italy, Belgium, Hungary, Poland, Romania, Denmark, Switzerland, Canada, France, Germany, Russian Federation, Turkey, United Kingdom, Spain, Austria, Portugal, Australia, Greece, South Africa, Bulgaria, Ukraine, Brazil, ... and more
Pfizer
Eli Lilly and Company; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co....

Recruiting

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Neoplasms

Canada, United States, Taiwan, Belgium, Korea, Republic of, Australia, China, Spain, New Zealand, Japan, Denmark, Germany, Netherlands, Italy, Russian Federation, Finland, Bulgaria, Czechia, India, Mexico, Slovakia, South Africa, Uk... and more
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
Merck Sharp & Dohme LLC

Recruiting

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Colorectal Cancer

United States, Belgium, Canada, Germany, Italy, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, United Kingdom, France, Denmark, Romania, Estonia, Hungary, Guatemala, Costa Rica, Lithuania, Greece, Colombia, Netherl...
GlaxoSmithKline

Completed

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)

Neoplasms, Prostate

United States, Australia, France, Germany, Spain, Bulgaria, Estonia, Italy, Poland, Netherlands, Belgium, United Kingdom, Canada, Denmark, Ukraine, Finland, Latvia, Russian Federation, Greece, Slovenia, Brazil, Mexico, Slovakia, Japan, Puerto... and more
AstraZeneca

Recruiting

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280)

Prostate Cancer

United States, China, Israel, Korea, Republic of, Canada, Poland, Spain, Belgium, Hungary, Japan, United Kingdom, France, Brazil, Taiwan, Australia, Turkey, Chile, Czechia, India, Mexico, Netherlands, Greece
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

Belgium, France, Germany, Spain, Sweden, Estonia, Portugal, Austria, Switzerland, Denmark, Czech Republic, Finland, Saudi Arabia, Netherlands, Norway
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Urinary Tract Cancer

Hungary, Italy, Australia, Czechia, United Kingdom, Austria, Belgium, Brazil, Bulgaria, Croatia, Denmark, Estonia, Greece, Portugal, Spain, Canada, India, Romania, Switzerland, Poland, Ireland, Colombia, Germany, Argentina, China, Lebanon, ... and more
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)

Metastatic Adenocarcinoma of the Pancreas | Germline BRCA1/2 Mutations and

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Germany, Korea, Republic of, Australia, Israel, Netherlands
Bayer
Amgen

Completed

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Carcinoma, Renal Cell

Italy, Spain, Canada, United States, Russian Federation, France, Australia, Chile, Germany, Hungary, Israel, United Kingdom, South Africa, Poland, Netherlands, Belgium, Ukraine, Argentina, Brazil
Astellas Pharma Global Development, Inc.
Pfizer

Recruiting

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Prostate Cancer

United States, Korea, Republic of, Japan, Belgium, Spain, Argentina, Australia, Canada, Chile, Czechia, Denmark, Finland, France, Georgia, Germany, Israel, Italy, Moldova, Republic of, New Zealand, Poland, Russian Federation, Slov... and more
Verastem, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201)

Ovarian Cancer | Low Grade Ovarian Serous Adenocarcinoma

Spain, United States, Belgium, United Kingdom, France, Canada, Italy
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Taiwan, Belgium, Denmark, Switzerland, Argentina, Israel, Italy, Croatia, United Kingdom, Korea, Republic of, Russian Federation, Slovakia, Japan, Bulgaria, Poland, Hungary, Australia, Turkey, Peru, Chile, Mexico, Czech... and more
Incyte Corporation

Terminated

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Pancreatic Cancer

United States, Italy, United Kingdom, Belgium, Germany, Taiwan, Spain, Korea, Republic of, Canada, New Zealand, Australia, Thailand
Arcagy Research
Belgian Gynaecological Oncology Group; Grupo Español de Investigación en Cáncer... and other collaborators

Completed

Platine, Avastin and OLAparib in 1st Line (PAOLA-1)

Ovarian Cancer

France, Germany, Austria, Denmark, Italy, Japan, Finland, Spain, Monaco, Sweden, Belgium
AstraZeneca

Recruiting

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Carcinoma, Non-Small-Cell Lung

United States, China, Korea, Republic of, Canada, Italy, Poland, Spain, Belgium, Netherlands, Japan, Germany, Brazil, Turkey, Russian Federation, United Kingdom, Greece, Israel, Australia, France, Puerto Rico
AstraZeneca

Completed

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Ovarian Cancer

Canada, Czechia, Poland, Romania, United States, Belgium, France, Russian Federation, United Kingdom, Israel, Spain, Germany, Austria, Netherlands, Australia, Estonia, Ukraine
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Non-Muscle Invasive Bladder Neoplasms

Korea, Republic of, United States, Argentina, Belgium, Brazil, China, Poland, United Kingdom, Italy, Japan, Germany, Romania
Merck Sharp & Dohme LLC
GOG Foundation; European Network for Gynaecological Oncological Trial groups(ENGOT)

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Endometrial Cancer

Poland, United States, Canada, Australia, Israel, Korea, Republic of, Spain, Chile, France, Puerto Rico, Greece, Netherlands, Norway, Singapore, Switzerland, Argentina, Austria, Belgium, Czechia, Denmark, Finland, Malaysia, Sweden, Italy and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)

Prostate Cancer

Romania, United States, Israel, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Singapor... and more
Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
Hoffmann-La Roche

Completed

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer

Belgium, Denmark, France, Germany, Portugal, Spain, Turkey, Bosnia and Herzegovina, Italy, Sweden, Finland, Netherlands, Norway, Greece
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
Bristol-Myers Squibb

Completed

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Transitional Cell Carcinoma | Bladder Cancer | Metastasis

United States, Korea, Republic of, United Kingdom, Spain, Australia, France, Thailand, Denmark, Poland, Belgium, Italy, Philippines, Canada, Russian Federation, Greece, Indonesia
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

Australia, United States, Korea, Republic of, Chile, Belgium, Italy, Spain, Israel, Japan
Mario Negri Institute for Pharmacological Research
PharmaMar; Averion International Corporation

Completed

INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (INOVATYON)

Ovarian Cancer

Austria, Belgium, Norway, Spain, Finland, United Kingdom, Italy, Denmark, Germany, Netherlands, Switzerland
Bayer

Terminated

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small Cell Lung

Belgium, Italy, Spain, Hong Kong, United States, Germany, United Kingdom, Chile, Taiwan, Australia, Canada, Argentina, Puerto Rico, France, Poland, Russian Federation, Sweden, Hungary, Netherlands, Brazil, Korea, Republic of
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)

Hepatocellular Carcinoma | Liver Cancer

United States, Canada, Germany, France, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Puerto Rico, Romania, Sing... and more
Pfizer

Completed

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Carcinoma, Non-Small Cell Lung

United States, Netherlands, Canada, Belgium, Spain, United Kingdom, Greece, Germany, Korea, Republic of, Poland, Russian Federation, Denmark, Chile, Colombia, Hungary, Czech Republic, Italy, Thailand, Brazil, Hong Kong, Taiwan, Sl... and more
Amgen

Completed

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

United States, Belgium, Czechia, Spain, Austria, France, Lithuania, Puerto Rico, Slovakia
Bristol-Myers Squibb

Completed

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Small Cell Lung Carcinoma

Germany, Korea, Republic of, Poland, Taiwan, United States, China, Hong Kong, Spain, Australia, Italy, Russian Federation, Mexico, France, Japan, Switzerland, Austria, Belgium, Canada, Czechia, Hungary, Ireland, Israel, Netherlands, Peru and more
Bristol-Myers Squibb

Completed

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

Head and Neck Cancer

United States, Brazil, Italy, South Africa, Spain, Canada, Argentina, Belgium, Chile, Czechia, Finland, France, Ireland, Mexico, Netherlands, Norway, Romania, Russian Federation, Sweden, Turkey, United Kingdom
AGO Research GmbH
Hoffmann-La Roche

Active, not recruiting

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Recurrent Ovarian Carcinoma

Norway, Spain, France, Switzerland, Denmark, Germany, Sweden, Belgium, Finland, Austria, Estonia, Lithuania
Telik

Completed

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Ovarian Neoplasms

United States, Czech Republic, South Africa, Argentina, Belgium, Spain, Brazil, Chile, Germany, Hungary, Ireland, Netherlands, United Kingdom
Pfizer
Astellas Pharma Inc

Active, not recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

United States, Finland, China, France, Spain, Hungary, United Kingdom, Korea, Republic of, Canada, Czechia, Taiwan, Belgium, Australia, Argentina, Japan, Germany, India, Turkey, Slovakia, Russian Federation, Bulgaria, Italy, Ukraine, ... and more
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Ovarian Cancer

United States, France, Poland, United Kingdom, China, Belgium, Germany, Hong Kong, Taiwan, Spain, Canada, Netherlands, Sweden, Korea, Republic of, Singapore, Russian Federation, Argentina, Brazil, Chile, Australia
Menarini Group

Terminated

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

Ovarian Cancer

United States, Spain, Germany, Belgium, France, Czech Republic, Hungary, Italy, Poland
Tesaro, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Neoplasms

United States, Canada, Netherlands, Spain, Finland, Belgium, Germany, Israel, Denmark, Sweden, United Kingdom, Poland, Hungary, Norway, Italy, Greece, Czechia, Ukraine, Belarus, Turkey
CanariaBio Inc.
Gynecologic Oncology Group; Iqvia Pty Ltd

Active, not recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Peritoneal Carcinoma | Peritoneal Cancer | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma

Korea, Republic of, United States, Taiwan, Czechia, Argentina, Spain, Belgium, Brazil, Chile, Canada, Italy, Hungary, India, Mexico
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Poland, Korea, Republic of, United States, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
Novartis Pharmaceuticals
GlaxoSmithKline

Completed

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer

China, United States, Belgium, Austria, Italy, Australia, France, Germany, Japan, Norway, Spain, Sweden, Korea, Republic of, Hong Kong, Denmark, Ireland, Taiwan
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Malaysia, Argentina, Hong... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)

Brain Cancer

United States, Canada, Belgium, Spain, Australia, Netherlands, United Kingdom, Denmark, Norway, Japan, Sweden, France, Poland, Austria, Germany, Israel, Italy, Russian Federation, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866)

Bladder Cancer

Canada, United States, Australia, Belgium, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom
Karyopharm Therapeutics Inc
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

Endometrial Cancer

United States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Germany, Czechia, Slovakia, Canada, Hungary

Clinical Trials on Lymphedema, Breast Cancer in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations